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Abstract—Conjugation of a lysosomotropic detergent to tumor affine peptides (octreotatee and melanocortin analogous) resulted in 
receptor mediated uptake of the peptide conjugates into tumor cells expressing the peptide receptors. During intracellular trafficking the 
lysosomotropic detergent was cleaved from the peptide. Cytotoxicity studies showed IC50 values in the range of 11-72 µM caused by 
lysosomal rupture as proven by confocal laser scanning microscopy. For cells not expressing the receptors the conjugates were less 
cytotoxic. 
Classical anticancer drugs lack specificity, as they enter 
the cells mainly by diffusion (1). Due to their DNA 
reactivity anticancer drugs can cause a second tumor 
several years after a curative treatment. Another strategy 
that might be exploited for cancer therapy is the 
controlled rupture of lysosomes (2-5). This treatment 
lacks the mutagenic potential of currently used 
chemotherapeutic agents. Tertiary amines that contain a 
hydrophobic chain, have been shown to accumulate in 
acidic cell organelles and become detergents upon 
protonation inside the acidic organelles resulting in 
organelle rupture and cell death (2). At neutral pH, they 
are rarely protonated and have no surface-active 
properties (2). It has been reported that lysosomal 
proteases, if released to the cytosol, may cause 
apoptosis directly by pro-caspase activation and/or 
indirectly by mitochondrial attack with ensuing 
discharge of pro-apoptotic factors (4). In cells with no 
lysosomes or small amounts of acidic cell organelles, 
lysosomotropic detergents were shown to be non-
cytotoxic (5). The cytotoxic effect of lysosomotropic 
detergents is best in cells with high amounts of acidic 
cell organelles – such as  cancer cells. The lipophilic 
nature of lysosomotropic detergents results in 
inselective cell uptake by passive diffusion through the 
lipid bilayer and cytotoxicity for cancer cells and 
normal cells. In order to increase the selectivity of 
lysosomotropic detergents, we propose the following 
strategy. By coupling lysosomotropic detergents to 
tumor affine peptides, they should become more water 
soluble. As the peptide derivatives of lysosomotropic 
detergents are more hydrophilic and do not diffuse 
passively through the lipid bilayer, involvement of the 
peptide receptor is essential for the cellular uptake of 
the conjugates. A further benefit of these conjugates 
should be the fact, that by exploiting the physiological 
transport process of the peptide-receptor complexes the 
peptide-conjugates are targeted to the lysosomes, the 
compartment where lysosomotropic detergents are 
activated. Receptor mediated cell uptake is supposed to 
be followed by intralysosomal, enzymatic liberation of 
the lysosomotropic detergent moiety. Employing this 
strategy should provide a more selective exploitation of 
the lysosomotropic detergents in cancer therapy. 
Peptides are used as targeting moieties in cancer therapy 
(6). Conjugates of chemotherapeutic agents and 
peptides can significantly increase the toxicity of 
anticancer drugs to tumors and reduce their adverse side 
effects on normal tissues (7). Somatostatin receptors 
(SSTR) have been found in a variety of neuroendocrine 
tumors, such as carcinoids and paragangliomas, as well 
as in most pancreatic endocrine and breast tumors (8). 
Structure–activity relationship studies have shown that 
the N-terminus of the cyclic octapeptides octreotatee (a 
somatostatin analogous) can tolerate N terminal 
substitution with minimal effect on SSTR affinity and 
internalization rate (9, 10). The Tyr3 modification of the 
peptide moiety was shown to result in a favourable 
pharmacokinetic behavior (9, 10). Melanoma cells 
display melanocortin stimulating hormone receptors. 
MSH analogous have been shown not to lose their 
receptor affinity when they contain N terminal 
substituents (11-13). For this reason octreotate (H-DPhe-
cyclo(Cys-Tyr-DTrp-Lys-Thr-Cys)-Thr-OH) and a 
mela-nocortin analogous (His-Phe-Arg-Trp-NH2) were 
chosen as tumor affine peptide carriers for the 
lysosomotropic detergent (11-13). We propose of 
coupling lysosomotropic detergents to tumor affine 
peptides might provide a new, more selective anticancer 
drugs. We synthesized and characterized the conjugates 
and evaluated their in vitro cytotoxicity, cell uptake 
characteristics and their mode of action. Scheme 1 
shows the structures of the conjugates as well as the 
supposed intracellular cleavage. The lysosomotropic 
detergent Laur(OH) was obtained by reacting N,N´-
bis(hydroxyethyl)ethylendiamine with dodecanoic acid 
using HATU (=HATU (O-(7-azobenzo-. triazol-1-yl)-
1,1,3,3-tetramethyluronium) as amidation reagent.  For 
coupling Laur(OH) to tumor affine peptides it was 
reacted with S-acetylmercaptoacetic acid-
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pentafluorophenylester (SAMA-OPfp) to form 
Laur(OH)-SAMA (14). Scheme 2 shows the synthetic 
route of Laur(OH)-SAMA. After deprotection of 
Laur(OH)-SAMA with hydroxylamine a Michael 
addition was performed to link the lysosomotropic 
detergent to the thiol reactive maleimido modified 
peptides (14). According to the Merrifield strategy, the 
peptides (octreotate and a melanocortin analogous) 
containing a maleimido moiety were synthesized 
manually. The peptides were synthesized manually, 
according to the Merrifield strategy. 9-
Fluorenylmethoxycarbonyl (Fmoc) amino acids were 
coupled in a stepwise manner to the corresponding 
resin. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyl-
uronium hexafluorophosphate (HBTU) in DMF was 
used as coupling agent. Fmoc groups were removed 
using 20% piperidine/DMF. In the case of octreotatee 
the linear peptide H-DPhe-Cys(Acm)-Tyr(tBu)-DTrp(Boc)-
Lys(Boc)-Thr(tBu)-Cys(Acm)-Thr(tBu)-OH was assembled 
by solid-phase synthesis, then the disulfide bond was 
formed on the solid support using 
thalliumtrifluoroacetate, and the N terminus was 
derivatized with a maleimido functionality (10). For the 
synthesis of the melanocortin analogous Fmoc-His(Trt), 
Fmoc-Phe, Fmoc-Arg(Pbf) and Fmoc-Trp(Boc) were 
used. The peptides were cleaved from the resin with 
trifluoroacetic acid (TFA/H2O/triisopropylsilane 
(95:2.5:2.5). Reversed-phase HPLC purification of the 
crude products yielded the pure peptides which were 
characterized by analytical reversed-phase HPLC, and 
ion-spray mass spectrometry to reveal identity and 
purity.  
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Scheme 1: Synthesis of Laur(OH)-SAMA 
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Scheme 2: Chemical structures of the conjugates and intracellular 
hydrolysis.  
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Scheme 3: Intracellular hydrolysis of the conjugate. 
 
 
Viability measurements using the MTS non radioactive 
proliferation assay revealed that Laur-OH 
(unconjugated lysosomotropic detergent) showed 
toxicity against AR42J, MCF-7, ZR-75, 3T3NIH, B16, 
SkMel3 cells with IC50 values in the range of 19- 52 
µM. The octreotatee conjugates were cytotoxic for 
AR42J and MCF-7 cells (both overexpressing 
somatostatine receptors) compared to ZR-75 and 
3T3NIH cells (both expressing no somatostatine 
receptors). The MSH-conjugate was more cytotoxic for 
the MSH expressing cells B16 and SkMel3 compared to 
the other cells lines, all lacking MSH receptors. The 
IC50 values for each cell line and compound are given in 
Table 2. By coupling the lysosomotropic detergent to 
tumor targeting peptides their cytotoxicity for cells 
expressing the receptor is greater (lower IC50 value) and 
shows a preferential cytotoxicity for these cell lines. 
However, the compounds were cytotoxic for the cells 
not expressing the receptor. This can be explained by 
partial hydrolysis of the compounds. The hydrolysed 
proportion is taken up by passive diffusion and is 
cytotoxic. HPLC studies revealed a hydrolysis of about 
Compounds formula/ (M+H)+ 
calc. 
(M+H)+ found tR (min) 
 
Lau-OH 331.29 331.3 3.488 
Laur-Sama 447.28 447.3 3.842 
octreotatee 
conjugate 
1618.73 1618.9 3,514 
maleimido-
octreotatee 
1215.37 1215.4 2.803 
MSH conjugate 1213.65 1212.8 2.779 
maleimido-MSH 809.38 809.5 2.477 
  3 
40% at the ester bond after one hour incubations in cell 
culture medium at 37°C. The IC50 values for 
lysosomotropic detergents are in the µM range (2). Even 
the conjugates show a cytotoxicity in the µM range. 
This can be explained by the mode of action. The 
detergents are incorperated into the lysosomal 
membrane (2). Only a µM concentration can destroy the 
lysosomal membrane. The conjugates are more effective 
compared to the unconjugated lysosomotropic detergent 
as allow more effective transport to the lysosomes. 
 
Table 2. Results of the cytotoxicity assay  for compounds 1–6. 
Compd cell line Cytotoxicity 
IC50, µMa 
Compd     cell line Cytotoxicity 
IC50, µMa 
Laur-OH AR42J 25 (±8)   OC AR42J 11 (±8) 
Laur-OH MCF-7 34 (±5) OC  MCF-7 20 (±8) 
Laur-OH ZR-75 37 (±8) OC ZR-75 55 (±8) 
Laur-OH 3T3NIH 52 (±14) OC 3T3NIH 64 (±8) 
Laur-OH B16 19 (±8) MSH SkMel3 15 (±8) 
Laur-OH SkMel3 28 (±8) MSH B16 25 (±8) 
   MSH 3T3NIH 72 (±8) 
aValues are means of three experiments, standard deviation is given in 
parentheses. OC = octreotatee conjugate, MSH = MSH conjugate. 
 
In order to prove that disrupture of lysosomal 
membranes is mediated by the lysosomotropic detergent 
and the peptide conjugates, the localization of 
lysosomal entrapped FITC(fluorescein isothiocyanate)-
dextran in B16, 3T3 NIH, AR42J, MCF-7 and ZR-75 
cells was studied in the presence and in the absence of 
the lysosomotropic detergent and the peptide 
conjugates. FITC-dextran is a macromolecular drug that 
localises to acidic organelles by endocytosis and that is 
unable to escape from these organelles (15). Viable cells 
incubated with FITC-dextran alone served as controls. 
In the control cells FITC-dextran was located in 
lysosomes and endosomes, but not in other subcellular 
structure. An additional treatment of the cells with a 
peptide conjugate or a lysosomotropic detergent led to a 
change in the subcellular distribution of FITC-dextran 
which could now be imaged in the cytoplasm. There 
was a concentration dependent influence on the 
subcellular distribution of FITC-dextran. Incubation 
concentrations near the IC50 values resulted in a release 
of FITC-dextran into the cytoplasm. The micrographs of 
MCF-7 cells in Figure 1 show the subcellular 
distribution of FITC-dextran in the absence and in the 
presence of Laur-OH. FITC-dextran is located in the 
cytoplasm of cells treated with Laur-OH. Similar results 
were obtained in the with the octreotatee conjugate (not 
shown). The same changes in the subcellular 
distribution of FITC-dextran were obtained by 
Prasmickaite et al. who disrupted the endosomal 
membranes by photochemical delivery [15]. 
The data presented in this paper support the further 
evaluation of conjugates as novel targeted anticancer 
drugs. 
 
 
 
 
 
Figure 1: Subcellular distribution of fluoresceinisothiocyanate-dextran in 
the absence (a and b) and presence of a  lysosomotropic detergent or a 
peptide conjugate in MCF-7 cells. 
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Experimental 
 
Materials and Methods. The protected amino-acids 
were obtained from Merck (Darmstadt, Germany). All 
other chemicals were obtained from Sigma-Aldrich 
(Taufkirchen, Germany). The peptides were analyzed 
and purified by liquid chromatography (HPLC) on an 
Agilent 1100 system (Waldbronn, Germany) equipped 
with a variable UV detector. The columns used were 
Chromolith® RP- (5 µm, 250×4 mm; 10 µm, 250×10 
mm; (VWR International GmbH, Darmstadt, Germany). 
All analytical runs were performed with at a flow rate of 
4 mL/min. Unless otherwise stated, all preparative runs 
were performed with a linear gradient over 10 min of 0–
100% acetonitrile in water (both solvents containing 
0.1% TFA) and a flow rate of 8 mL/min. The peptides 
were synthesized manually. Low-resolution mass 
spectrometric analysis (ca. ±2 m.u.) of the peptides and 
conjugates was performed on a matrix-assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometer (MALDI-1, Kratos Instruments, UK). Sample 
preparation was performed with a solution of 2′-(4-
hydroxyphenylazo)benzoic acid in acetonitrile/water (1:1) 
containing 0.1% TFA. The matrix (0.6 µL) was placed on 
the target, followed by one drop (0.6 µL) of the analyte, 
and allowed to dry at room temperature. Analyses with 
higher resolution and absolute accuracy were obtained 
with a Reflex 3 MALDI-TOF (Bruker Daltonics) 
(accuracy: ca. ±0.5 m.u.) and confirmed with a Finnigan 
MAT TSQ-7000 triple-quadrupole mass spectrometer 
using electrospray ionization (ESI) in the positive-ion 
mode (accuracy: ca. ±0.4 m.u.). 
 
Synthesis and analytical data 
 
Laur(OH). 2 g (10 mmol) dodecanoic acid and 3.8 g 
(10 mmol) mg HATU were dissolved in 3 mL of 
acetonitrile. Then 1.48 g (10 mmol) of N,N´-
bis(hydroxyethyl)ethylendiamine were added and the 
reaction mixture was stirred at ambient temperatur for 
one hour. The reaction mixture was evaporated to 
dryness and then dissolved in dichlormethane. The 
organic phase was extracted several times with 1 N 
NaOH. The organic phase was dried over MgS04 and 
then purified by column chromatography (silica gel/ 
solvent: CHCl3: MeOH : Et3N = 80:18:2). Evaporation 
to dryness resulted in a white powder. 
Laur-OH-Sama. To a stirred solution of Laur(OH) in 
dichlormethane was added a solution of SAMA at 
ambient temperature at a dropwise manner over 2 hours. 
Then the reaction mixture was washed with 1 N NaOH. 
The organic phase was dried over MgSO4 evaporated to 
dryness. Column chromatography (silica gel/ solvent: 
CHCl3: MeOH : Et3N = 95:4:1) and evaporation to 
dryness resulted in a yellowish oil.  
 
Maleimido-MSH was assembled by Fmoc chemistry 
on Rink amide resin (0.61 mmol/g). N α -Fmoc amino 
acids with the following side chain protecting groups 
were employed: Trp(Boc), Arg(Pbf), Phe and His(Trt). 
N-maleimido-3-propionic acid was coupled as described 
above, the resin was washed and dried under vacuum 
overnight. Cleavage was performed with 5 mL of 
37:1:1:1 TFA/H2O/phenol/TIS for 2 h at room 
temperature. The resin was filtered and washed. The 
peptide was precipitated by the gradual addition of tert-
butyl-methylether at 4 °C. Purification was 
accomplished by reversed-phase HPLC.  
 
Maleimido-octreotatee was assembled by Fmoc 
chemistry on Fmoc-Thr(tBu)-Wang resin (0.61 
mmol/g). N α -Fmoc amino acids with the following 
side chain protecting groups were employed: Cys(Acm), 
Thr(tBu), Lys(Boc), Trp(Boc), D-Phe, D-Trp(Boc), and 
Tyr(tBu). All couplings were performed in DMF. The 
peptide chain was constructed manu-ally according to a 
modified in situ neutralisation cycle. Briefly, this cycle 
consisted of a twofold decoupling (1 min and 5 min) 
with 50 % piperidine in DMF and 30 min coupling with 
4 eq of the Fmoc-amino acid (0.4 M in DMF, incubated 
for 5 min with 3.9 eq of HBTU and 6 eq DIPEA). After 
completion, the resin (1.75 g dry weight) was treated 
with piperidine in DMF to deprotect the terminal α -
aminogroup of the peptide.  The resin-bound peptide 
was cyclized at room temperature with a 4-fold molar 
excess of thallium(III)trifluoroacetate in dichlormethane 
for one45 minutes. After thorough washing, N-
maleimido-3-propionic acid was coupled as described 
above, the resin was washed and dried under vacuum 
overnight. Cleavage was performed with 5 mL of 
37:1:1:1 TFA/H2O/phenol/TIS for 2 h at room 
temperature. The resin was filtered and washed. The 
peptide was precipitated by the gradual addition of tert-
butyl-methylether at 4 °C. Purification was 
accomplished by reversed-phase HPLC. 
 
Conjugation of the lysosomotropic detergent to the 
peptide 
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Preparation of the hydroxylamine solution. To 34 µL 
of a 50% hydroxylamine solution in water 966 µL water 
were added.  
 
MSH conjugate. 43 mg (50 µmol) of the 
maleimidopropionic acid-His-Phe-Arg-Trp-NH2 peptide 
and 22 mg (50 µmol) of the Laur(OH)sama were 
dissolved were dissolved in a mixture consisting of 2 
mL PBS buffer (0.4 M, pH = 6.4), 600 µL DMSO and 
400 µL of the aforementioned hydroxylamine solution. 
The resulting pH should be in the range of 7.0 to 7.5. 
The reaction mixture was vortexed for 2 minutes 
resulting in a precipitate. The precipitate was sseparated 
from the supernatant and dissolved in acetonitril water 
containing TFA. This solution was purified by 
preparative HPLC. The conjugate eluting at 5.714 min 
was collected and lyophilised. 11 mg of a white powder 
(68 % based on the amount of the starting maleimido-
peptide) was obtained. 
 
Octreotate conjugate. 21 mg (49 µmol) of 
Laur(OH)sama and 60 mg (49 µmol) of maleimido-
3Tyr-octreotatee were dissolved in a mixture consisting 
of 2 mL PBS buffer (0.4 M, pH = 6.4), 600 µL DMSO 
and 400 µL of the aforementioned hydroxylamine 
solution. The resulting pH should be in the range of 7.0 
to 7.5. The reaction mixture was vortexed for 2 minutes 
resulting in a precipitate. The precipitate was sseparated 
from the supernatant and dissolved in acetonitril water 
containing TFA. This solution was purified by 
preparative HPLC. The conjugate eluting at 5.714 min 
was collected and lyophilised. 7.85 mg of a white 
powder (68 % based on the amount of the starting 
maleimido-peptide) was obtained. 
 
Stability. The conjugate was dissolved in cell culture 
medium and incubated for 1 hour at 37°C. Then a 
HPLC analysis was made using the conditions 
mentioned above. 
 
Biological experiments. 
FITC-dextran assay  
Cells grown on coverslips were incubated with 1 mg/ml 
FITC-dextran (MW 70000) for 24 h. Afterwards they 
were incubated with or without Laur(OH) or a 
conjugate for 1 h at indicated concentrations (in the 
range of 10–200 µmol/l). Cells were washed three times 
with PBS buffer. The intracellular localization of FITC-
dextran in unfixed cells was observed with a Zeiss 
Axioplan fluorescence microscope (Oberkochen, 
Germany) using an objective with ×100, a 450–490 nm 
bandpass excitation filter and a 510–540 bandpass 
emission filter. 
 
Viability assay 
The MTS viability assay (Cell Titer 96® Aqueous non-
radioactive proliferation assay; Promega, Madison, WI, 
USA) was performed according to the manufacturer's 
instructions. B16 (murine melanoma), SK-MEL-3 
(human melanoma), AR42J (rat pancreas carcinoma), 
MCF-7 (human breast cancer), ZR-75 (human breast 
cancer) and NIH 3T3 (mouse fibroblast) cells were 
obtained from the tumour bank of the DKFZ 
(Heidelberg, Germany). Melanocytes were obtained 
from Promo Cell (Heidelberg, Germany). The cells 
were cultured for 24 h in a 96-well microtitre plate at 
37°C in an atmosphere of 95% air and 5% CO2. The 
culture medium consisted of RPMI-1640 and 
Dulbecco's phosphate-buffered saline (DPBS) (both 
from Pan Biotech, GmbH, Aidenbach, Germany). After 
24 h, the cells were incubated with the compounds at 
indicated concentrations. The fraction of surviving cells 
was measured 48 h later, measuring the lactate 
dehydrogenase (LDH)-induced formazan formation at 
490 nm with a microplate reader model 3350-UV 
(Biorad Laboratories GmbH, München, Germany). The 
compounds were dissolved in dimethylsulphoxide 
(DMSO) at a concentration of 100 mM to serve as stock 
solutions. The final concentrations in contact with the 
cells were 0, 1, 10, 25, 50, 75, 100 and 250 µM. 
